Literature DB >> 28189547

Role of microRNA-29a in the development of diabetic retinopathy by targeting AGT gene in a rat model.

Li-Qiong Zhang1, Hao Cui2, Lin Wang2, Xu Fang2, Sheng Su2.   

Abstract

OBJECTIVES: This study intends to explore the role of microRNA-29a (miRNA-29a) in the development of diabetic retinopathy by targeting AGT gene in a rat model.
METHODS: Fifty-six DR rat models were established and divided into 7 groups (with 8 rats in each group): the model group, the miRNA-29a group, the miRNA-29a knockdown group, the negative control (NC) group, the AGT group, the miRNA-29a+AGT group, and the miRNA-29a knockdown+AGT group respectively, while 8 normal rats were selected as the normal group. The qRT-PCR was used to detect the expression of miRNA-29a and AGT mRNA. The AGT protein expression was measured using Western blotting. The ADPase histochemical staining was applied to detect retinal neo-vascular morphology. The number of retinal vascular endothelial cells was counted by H&E staining.
RESULTS: MiRNA-29a and AGT mRNA expressions were negatively correlated. Compared with rats in the normal group, the miRNA-29a expression in DR rats of each group decreased, but the AGT mRNA and protein expression increased; the vascular distribution was in disorder, and the new retinal vessels, vascular density, and endothelial nuclei all increased. Compared with the model group, miRNA-29a increased, and the AGT mRNA and protein expression decreased in the miRNA-29a group; additionally, the vascular density, tortuosity, and endothelial cell nuclei significantly decreased. The opposite trend was found in the miRNA-29a knockdown group, the miRNA-29a knockdown+AGT group, and the AGT group, particularly in the miRNA-29a knockdown+AGT group.
CONCLUSION: Overexpression of miRNA-29a could down-regulate AGT expression, thereby preventing the development of DR in a rat model.
Copyright © 2017 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Angiotensinogen; Diabetic retinopathy; Endothelial cell nucleus; MicroRNA-29a; Rat model; Retinal neovascularization; Vascular density

Mesh:

Substances:

Year:  2017        PMID: 28189547     DOI: 10.1016/j.yexmp.2017.02.004

Source DB:  PubMed          Journal:  Exp Mol Pathol        ISSN: 0014-4800            Impact factor:   3.362


  7 in total

1.  A therapeutic approach towards microRNA29 family in vascular diabetic complications: A boon or curse?

Authors:  Aishwarya P Dasare; Piyush Gondaliya; Akshay Srivastava; Kiran Kalia
Journal:  J Diabetes Metab Disord       Date:  2019-05-11

2.  Salidroside alleviates high-glucose-induced injury in retinal pigment epithelial cell line ARPE-19 by down-regulation of miR-138.

Authors:  Cheng Qian; Shenzhi Liang; Guangming Wan; Yi Dong; Taiying Lu; Panshi Yan
Journal:  RNA Biol       Date:  2019-07-11       Impact factor: 4.652

3.  Bone marrow mesenchymal stem cells-induced exosomal microRNA-486-3p protects against diabetic retinopathy through TLR4/NF-κB axis repression.

Authors:  W Li; L Jin; Y Cui; A Nie; N Xie; G Liang
Journal:  J Endocrinol Invest       Date:  2020-09-26       Impact factor: 4.256

4.  A comprehensive competitive endogenous RNA network pinpoints key molecules in diabetic retinopathy.

Authors:  Yingcheng Wu; Keren Jia; Huiqun Wu; Aimin Sang; Lei Wang; Lili Shi; Kui Jiang; Jiancheng Dong
Journal:  Mol Med Rep       Date:  2018-12-03       Impact factor: 2.952

5.  MiRNA-144-3p inhibits high glucose induced cell proliferation through suppressing FGF16.

Authors:  Cuimin Chen; Chunyan Zhao; Cao Gu; Xiao Cui; Jinhui Wu
Journal:  Biosci Rep       Date:  2019-07-25       Impact factor: 3.840

Review 6.  Roles of miRNAs and long noncoding RNAs in the progression of diabetic retinopathy.

Authors:  Qiaoyun Gong; Guanfang Su
Journal:  Biosci Rep       Date:  2017-11-29       Impact factor: 3.840

7.  MicroRNA-139-5p Alleviates High Glucose-Triggered Human Retinal Pigment Epithelial Cell Injury by Targeting LIM-Only Factor 4.

Authors:  Kan Shao; Gong Chen; Lili Xia; Cheng Chen; Shan Huang
Journal:  Mediators Inflamm       Date:  2021-10-23       Impact factor: 4.711

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.